39.59
Atricure Inc stock is traded at $39.59, with a volume of 1.28M.
It is down -6.54% in the last 24 hours and up +15.12% over the past month.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
See More
Previous Close:
$42.36
Open:
$42
24h Volume:
1.28M
Relative Volume:
2.73
Market Cap:
$1.93B
Revenue:
$447.57M
Net Income/Loss:
$-38.92M
P/E Ratio:
-47.70
EPS:
-0.83
Net Cash Flow:
$-1.15M
1W Performance:
-3.34%
1M Performance:
+15.12%
6M Performance:
+76.03%
1Y Performance:
+24.85%
Atricure Inc Stock (ATRC) Company Profile
Name
Atricure Inc
Sector
Industry
Phone
513-755-4100
Address
7555 INNOVATION WAY, MASON, OH
Compare ATRC with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ATRC
Atricure Inc
|
39.59 | 1.93B | 447.57M | -38.92M | -1.15M | -0.83 |
![]()
ISRG
Intuitive Surgical Inc
|
591.39 | 210.92B | 8.35B | 2.32B | 1.30B | 6.41 |
![]()
BDX
Becton Dickinson Co
|
225.01 | 64.61B | 20.64B | 1.73B | 2.94B | 6.02 |
![]()
ALC
Alcon Inc
|
90.24 | 44.63B | 9.76B | 1.16B | 665.00M | 2.34 |
![]()
RMD
Resmed Inc
|
239.48 | 35.18B | 4.93B | 1.25B | 1.38B | 8.47 |
![]()
COO
The Cooper Companies, Inc.
|
93.68 | 18.66B | 3.90B | 392.30M | 288.10M | 1.95 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-17-24 | Resumed | JP Morgan | Overweight |
Apr-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
Sep-29-23 | Initiated | UBS | Buy |
Aug-05-21 | Downgrade | Oppenheimer | Outperform → Perform |
Dec-18-20 | Reiterated | Needham | Buy |
Nov-06-20 | Reiterated | Needham | Buy |
Apr-07-20 | Initiated | Oppenheimer | Outperform |
Feb-06-20 | Initiated | BTIG Research | Buy |
Jan-24-20 | Reiterated | Needham | Buy |
Aug-13-19 | Downgrade | Northland Capital | Outperform → Market Perform |
Apr-12-19 | Initiated | JP Morgan | Overweight |
Oct-04-18 | Reiterated | Needham | Buy |
Aug-02-18 | Reiterated | Needham | Buy |
Aug-02-18 | Reiterated | Stifel | Buy |
Jun-18-18 | Reiterated | Needham | Buy |
Apr-27-18 | Reiterated | Needham | Buy |
Jan-16-18 | Reiterated | Needham | Buy |
Nov-02-17 | Reiterated | Needham | Buy |
Jul-28-17 | Reiterated | Needham | Buy |
May-30-17 | Resumed | Piper Jaffray | Overweight |
Jun-30-16 | Resumed | JMP Securities | Mkt Outperform |
Oct-28-15 | Reiterated | Needham | Buy |
Oct-06-15 | Reiterated | Canaccord Genuity | Buy |
Oct-06-15 | Reiterated | Needham | Buy |
View All
Atricure Inc Stock (ATRC) Latest News
AtriCure’s Earnings Call Highlights Strong Growth and Positive Outlook - TipRanks
AtriCure (ATRC) Reports Q4 Loss, Lags Revenue Estimates - MSN
AtriCure (NASDAQ:ATRC) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know - Nasdaq
AtriCure price target raised to $57 from $53 at BTIG - TipRanks
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? - Yahoo Canada Finance
AtriCure price target raised to $48 from $36 at Stifel - TipRanks
AtriCure price target raised to $50 from $40 at Piper Sandler - TipRanks
WCM Investment Management LLC Lowers Stock Position in AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
Earnings call transcript: AtriCure Q4 2024 revenue rises, stock dips By Investing.com - Investing.com South Africa
Silver Oak Securities Incorporated Purchases Shares of 7,278 AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
AtriCure Inc (ATRC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
AtriCure, Inc. Reports Strong 2024 Financial Growth - TipRanks
AtriCure targets $517M-$527M revenue in 2025 with new product launches and international growth - MSN
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results - BioSpace
AtriCure: Q4 Earnings Snapshot - Midland Daily News
Earnings call transcript: AtriCure Q4 2024 revenue rises, stock dips - Investing.com
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings - Yahoo Finance
AtriCure Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AtriCure: Q4 Earnings Snapshot -February 12, 2025 at 04:39 pm EST - Marketscreener.com
AtriCure Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Earnings Flash (ATRC) ATRICURE INC. Reports Q4 Revenue $124.3M, vs. FactSet Est of $121.3M - Marketscreener.com
AtriCure's (ATRC) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS - MSN
JMP reiterates AtriCure stock with $60 target, sees growth - MSN
Expert Outlook: AtriCure Through The Eyes Of 5 Analysts - Benzinga
JMP reiterates AtriCure stock with $60 target, sees growth By Investing.com - Investing.com Canada
Calamos Advisors LLC Purchases 24,147 Shares of AtriCure, Inc. (NASDAQ:ATRC) - MarketBeat
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of “Buy” from Brokerages - Armenian Reporter
Transcatheter Aortic Valve Replacement Market Future Business - openPR
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know - Nasdaq
Atrial Fibrillation Systems Market Witness Booming Demand: - openPR
AtriCure (NASDAQ:ATRC) Stock Price Down 4.9%Should You Sell? - MarketBeat
AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Rating of “Buy” by Brokerages - Defense World
AtriCure (NASDAQ:ATRC) Sets New 1-Year HighHere's What Happened - MarketBeat
Why AtriCure, Inc. (ATRC) Is Skyrocketing Now - MSN
AtriCure (NASDAQ:ATRC) Price Target Raised to $51.00 - Defense World
Trading (ATRC) With Integrated Risk Controls - Stock Traders Daily
Atricure Inc Stock (ATRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):